Pharmaceuticals France

France Allergy Immunotherapy Market Analysis, 2024–2034

France Allergy Immunotherapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Allergen, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $62.8 Mn Estimated value
Estimate 2025 $67.2 Mn 2.9% of the global market
Projected 2034 $123.6 Mn 83.8% Adds $56.3 Mn over 9 forecast years
CAGR 2025–2034 7.0% Faster than 50% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • France is 2.88% of the global market.
  • In Europe, the largest is Germany at $74.3 Mn.
  • Fastest growing: Russia at 8.1% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$56.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Allergy Immunotherapy Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $62.8 Mn — —
2025 (base) $67.2 Mn +$4.4 Mn —
2026 (forecast) $71.9 Mn +$4.7 Mn +7%
2027 (forecast) $76.9 Mn +$5.0 Mn +14.5%
2028 (forecast) $82.3 Mn +$5.4 Mn +22.5%
2029 (forecast) $88.1 Mn +$5.8 Mn +31.1%
2030 (forecast) $94.3 Mn +$6.2 Mn +40.3%
2031 (forecast) $100.9 Mn +$6.6 Mn +50.1%
2032 (forecast) $107.9 Mn +$7.1 Mn +60.6%
2033 (forecast) $115.5 Mn +$7.6 Mn +71.8%
2034 (forecast) $123.6 Mn +$8.1 Mn +83.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

The France Allergy Immunotherapy Market Analysis Executive Summary

Allergy immunotherapy gradually trains the immune system to tolerate allergens, using shots, tablets or drops.

Key segments of the allergy Immunotherapy market include type (Subcutaneous Immunotherapy, Sublingual Tablets and Sublingual Drops) and allergen (Pollen, Dust Mites and Food).

France Allergy Immunotherapy Market Dynamics

Market Growth Drivers

More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the allergy Immunotherapy market. Biosimilars are widening access.

Opportunity

New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the allergy Immunotherapy market room to grow.

Market Restraints

High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the allergy Immunotherapy market.

Competitive Landscape for Allergy Immunotherapy Market in France

The allergy Immunotherapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Allergy Immunotherapy Market in France

Allergy Immunotherapy in France: rules and payment

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for allergy Immunotherapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Allergy Immunotherapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Allergy Immunotherapy in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

Questions, answered with public data

How much research is published on Allergy Immunotherapy?
PubMed lists 132 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on allergies and biologics and biosimilars

See the topic